Core Insights - The 2025 Analyst Conference has commenced, gathering top analysts, fund managers, and scholars to explore investment opportunities across market cycles [1] Group 1 - The event features a convergence of leading figures from both research and investment sectors, emphasizing deep research and value discovery [1]

Core Insights - The 2025 Analyst Conference has officially commenced, gathering top industry researchers, public and private fund leaders, and authoritative scholars to explore investment truths across cycles [4]. Group 1 - The event features a convergence of elite forces from both the research and investment sectors, emphasizing deep research and value discovery [4]. - The conference is referred to as the "Oscars" of the capital markets, highlighting its significance in the industry [3].

专题：2025分析师大会：资本市场"奥斯卡"启幕 华安基金总经理张霄岭 责任编辑：张恒星 11月28日，2025分析师大会重磅启幕，百位行研首席、公私募掌舵人、权威学者齐聚一堂，共寻穿越周期的投资真谛。 本次盛会汇聚了来自研究界与投资界的顶尖力量。让我们，共同以深度研究，共赴时代之约，做价值发现者！ 华安基金总经理张霄岭出席2025分析师大会暨第七届新浪财经金麒麟分析师盛典。 ...

专题：2025分析师大会：资本市场"奥斯卡"启幕 中欧基金董事长窦玉明出席2025分析师大会暨第七届新浪财经金麒麟分析师盛典。 中欧基金董事长窦玉明 责任编辑：张恒星 11月28日，2025分析师大会重磅启幕，百位行研首席、公私募掌舵人、权威学者齐聚一堂，共寻穿越周期的投资真谛。 本次盛会汇聚了来自研究界与投资界的顶尖力量。让我们，共同以深度研究，共赴时代之约，做价值发现者！ ...

博道基金董事长莫泰山出席2025分析师大会暨第七届新浪财经金麒麟分析师盛典。 博道基金董事长莫泰山 责任编辑：张恒星 专题：2025分析师大会：资本市场"奥斯卡"启幕 11月28日，2025分析师大会重磅启幕，百位行研首席、公私募掌舵人、权威学者齐聚一堂，共寻穿越周期的投资真谛。 本次盛会汇聚了来自研究界与投资界的顶尖力量。让我们，共同以深度研究，共赴时代之约，做价值发现者！ ...

东方港湾创始人兼董事长但斌 专题：2025分析师大会：资本市场"奥斯卡"启幕 11月28日，2025分析师大会重磅启幕，百位行研首席、公私募掌舵人、权威学者齐聚一堂，共寻穿越周期的投资真谛。 本次盛会汇聚了来自研究界与投资界的顶尖力量。让我们，共同以深度研究，共赴时代之约，做价值发现者！ 东方港湾创始人兼董事长但斌出席2025分析师大会暨第七届新浪财经金麒麟分析师盛典。 责任编辑：张恒星 ...

专题：2025分析师大会：资本市场"奥斯卡"启幕 11月28日，2025分析师大会重磅启幕，百位行研首席、公私募掌舵人、权威学者齐聚一堂，共寻穿越周 期的投资真谛。 本次盛会汇聚了来自研究界与投资界的顶尖力量。让我们，共同以深度研究，共赴时代之约，做价值发 现者！ 责任编辑：刘万里 SF014 TV sina 新浪财经 e Both 10 - Reports B 七星新浪MILE HOME TR 18 10 21 最佳分餐员工程 金缺工事之意 中方文法位置 R J 4 s 9 3 E CONSULERS ...... 在专业工程 +124 & VT 117.7 sina新浪财经 Property of 第七届都会财经会印度 -1 最佳 分析 第 0.00 % 8 % ... ..... 在城市道 线 球员的女 本保设备 作者 人事人 & ***** as 分析师 sina 新浪财经 . e 七届新浪财经金麒麟分析师盛 首席合作伙伴:(A 分析师大会 ...

Core Insights - The 2025 Analyst Conference has commenced, gathering top research leaders, public and private fund managers, and authoritative scholars to explore investment truths across cycles [3]. Group 1 - The conference aims to unite leading figures from both the research and investment sectors to engage in deep research and value discovery [3].

【必读】新浪财经将于12月9日14：00举办金麒麟最佳投资顾问第二阶段参评及奖项评分说明会，请添加文末联系方式领取参会须知。 寻找优秀投顾、赋能投顾IP建设、共建展业平台——第二届新浪财经·金麒麟最佳投资顾问评选启动！新浪财经、微博两大平台同步传播投顾服务品牌、构 建投顾IP孵化机制、打造投顾社交展业平台！第二届新浪财经·金麒麟最佳投资顾问评选主办方为新浪财经，独家合作伙伴为银华基金。 公募基金模拟配置组评分说明>> | 评分项 | 收益率 | 最大回撤率 | 月均交易次数数 | 投资策略笔记 | | --- | --- | --- | --- | --- | | 评分占比 | 60% | 10% | 10% | 20% | | 満分要求 | 最高收益率得满分 | ≤10％得満分 | 月均交易次数≤3次得 | (3) 单笔交易笔记数量/总 | | | | | 满分 | 持仓 ETF 数≥80%得満分 5 | | | | | | 分; | | | | | | (4) 月度策略报告4次得满 | | | | | | 分 15分; | | 证分点明 | 按总收益率进行排 | 满足要求得满 | 满足要求得满分，若次 | ...

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]